HIGHLIGHTS
- who: Thais Tittanegro from the Institute of Liver and Digestive Health, University College London, United Kingdom have published the Article: Use of non-selective B-blockers is safe in hospitalised decompensated cirrhosis patients and exerts a potential anti-inflammatory effect: Data from the ATTIRE trial, in the Journal: (JOURNAL)
- what: The authors show that the use of NSBBs at hospitalisation was safe with no increased incidence of subsequent renal, cardiovascular other organ dysfunction during hospital stay compared to patients not prescribed.
- how: The authors compared baseline characteristics and incidence of renal and cardiovascular . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.